Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands.

J A SpoorendonkJean-Baptiste Brière Kevin BowrinA MillierM CoppensS TempelaarB Verheggen

Published in: Journal of medical economics (2021)

The cost-effectiveness analysis showed that rivaroxaban in combination with ASA is a cost-effective treatment option in stable CAD or PAD patients. Rivaroxaban in combination with ASA is even more cost-effective in high-risk subgroups.

Keyphrases

venous thromboembolism
atrial fibrillation
pulmonary embolism
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
coronary artery disease
prognostic factors
patient reported outcomes